A Cortellis Regulatory Intelligence alternative you can start today
This Cortellis Regulatory Intelligence alternative answers your pharma regulatory question in seconds, with source documents you can open. No demo to book.
Start self-serve, free to try, with no credit card.
Cortellis was a Thomson Reuters product until 2016 and is now part of Clarivate. RegAffairs AI answers questions about FDA approvals, Orange Book patents, EMA authorisations and shortages from the regulators' own records.
Cortellis Regulatory Intelligence at a glance
Clarivate's product page offers Cortellis through "Talk to us" and "Book a demo", with no published price. RegAffairs AI starts differently. Ask a question now, check the official citations and see the research trail before you choose a paid plan.
Why regulatory teams look for a Cortellis alternative
- An answer today, without a demo or a wait on procurement.
- A price you can see and expense, for one person or a small team.
- The regulator's own record behind every claim, ready to forward to a manager, a client or QA.
- Questions that cross from pharma into chemicals, food or cosmetics, like an excipient's CLP classification or a borderline supplement.
RegAffairs AI vs Cortellis Regulatory Intelligence, side by side
| RegAffairs AI | Cortellis (Clarivate) | |
|---|---|---|
| How you start | Ask your first question now, free, no credit card | Talk to us or book a demo |
| Pricing | Public: Free, Pro $100 per user per month, Enterprise on request | Not published |
Pharma regulatory answers cited to the official record
Ask in the language you work in. The agent searches the official registers and returns a quick answer in seconds. Pro can run deep research on harder questions. Each claim has an inline citation that opens the stored source, and the research trail is on the page.
These public answers were generated on 4 October 2026:
- Eliquis (apixaban) in the Orange Book. The answer lists US 6,967,208 expiring 21 Nov 2026, with a pediatric extension to 21 May 2027. US 9,326,945 runs to 24 Feb 2031 (pediatric to 24 Aug 2031). It also lists the 13 approved ANDAs, each linked to FDA's Orange Book entry.
- Mounjaro (tirzepatide) in the EU. The answer gives EMEA/H/C/005620, MAH Eli Lilly Nederland B.V., authorised 15 Sep 2022, latest Commission decision 25 Jun 2026. It also flags the PRAC aspiration signal behind a product-information update in July 2024.
- Amoxicillin shortages in four markets. One answer covers FDA, EMA, MHRA's SSP register and BfArM. It found one open BfArM report (ALIUD, expected to end 1 Dec 2026) and a resolved EMA notice. FDA's shortage records and MHRA's SSP register had no current entry at that check.
Pharma regulatory intelligence across 31 jurisdictions
Pharma coverage runs to 239 datasets across 31 jurisdictions. That includes FDA, EMA, the European Commission, HMA, MHRA, BfArM, ANSM, AIFA, CBG-MEB, Swissmedic, PMDA, Health Canada, TGA, CDSCO, MFDS, ANVISA, COFEPRIS and NMPA.
Ask for 2026 CGMP warning letters to drug manufacturers. This answer, generated on 4 October 2026, found 29 letters from January to September. It grouped the findings by 21 CFR 211 section and linked every letter on fda.gov.
The same corpus covers chemicals, food, cosmetics, pesticides and biocides: 1,201 datasets, 47 jurisdictions and 380+ regulators. An excipient's CLP classification is one more question, not another subscription.
Cortellis alternative pricing
RegAffairs AI is free to try, with no credit card. Pro is $100 per user per month: unlimited questions, deep research, the full corpus and every jurisdiction. Cancel anytime. Enterprise seats and procurement are available on request.
Clarivate doesn't publish a Cortellis price. Plans are on the pricing page.
Built for pharma regulatory teams of any size
- Regulatory affairs and market access at small and mid-size pharma and biotech: "Is tirzepatide centrally authorised in the EU, and since when?"
- Generics and portfolio teams: "Which Orange Book patents and exclusivities still cover apixaban?"
- Quality and GMP: "What is FDA citing in CGMP warning letters this year?"
- Supply teams: "Which markets currently report a shortage for this product?"
- Regulatory consultancies with several clients: "What is this product's approval status in the US and EU?"
More on RegAffairs AI for pharma, or see how it compares with hiring consultants.
FAQ
What is the best Cortellis Regulatory Intelligence alternative for a small team?
One you can start without a demo or a procurement cycle. RegAffairs AI is free to try with no credit card.
Are Cortellis and Thomson Reuters Regulatory Intelligence the same product?
No. Cortellis came from the Intellectual Property & Science business sold to Onex and Baring Private Equity Asia in October 2016, which became Clarivate. Thomson Reuters Regulatory Intelligence is a separate product for banking, financial services and insurance compliance, and CUBE completed its acquisition at the end of 2024.
How much does Cortellis cost compared with RegAffairs AI?
Clarivate does not publish Cortellis pricing, and buying starts with a demo. RegAffairs AI's price is public.
Is my data used to train models?
No. Questions are never used for training, and data is processed and stored in the EU by default. Details are on the security page.
Ask the question you'd have booked a demo for
Start with the Eliquis answer and open its Orange Book citations. Then ask about the product your team is researching.
More comparisons: RegAffairs AI vs ChatGPT, RegAffairs AI vs consultants, all comparisons.